Is a Potential Patent Waiver Bad News for Moderna?
Countries recently have discussed the possibility of waiving rights to vaccine patents during the pandemic. Their goal is to lift vaccine production and make vaccines more widely available. In this Motley Fool Live video recorded on May 28, 2021, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss whether a potential patent waiver might cut into sales of Moderna's (NASDAQ: MRNA) coronavirus vaccine.
Source Fool.com
